| Literature DB >> 31291058 |
Leah N Githinji1, Sana Mahtab1, Liesl Zühlke2,3, John Lawrenson4, Landon Myer5, Diane Gray1, Heather Zar1.
Abstract
INTRODUCTION: Antiretroviral therapy (ART) has reduced morbidity and mortality in sub-Saharan Africa, but the burden of coexistent cardiopulmonary disease in perinatally HIV-positive adolescents on antiretroviral therapy (ART) has not been well described. The aim of this study was to investigate the prevalence and associations of cardiopulmonary dysfunction in adolescents with perinatally acquired HIV on ART.Entities:
Keywords: HIV care continuum; South Africa; adolescents; antiretroviral therapy; cardiopulmonary dysfunction; perinatal HIV infection
Mesh:
Substances:
Year: 2019 PMID: 31291058 PMCID: PMC6619484 DOI: 10.1002/jia2.25340
Source DB: PubMed Journal: J Int AIDS Soc ISSN: 1758-2652 Impact factor: 5.396
Figure 1Flow diagram for the study population
6MWT, six‐minute walk test.
Baseline characteristics of study population
| Variable | HIV‐positive n = 474 | HIV‐uninfected n = 109 |
|
|---|---|---|---|
| Age, years | 12.0 (1.6) | 11.8 (1.8) | 0.257 |
| Male, n % | 247 (51.7) | 47 (45.2) | 0.231 |
| Height | −1.3 (1.1) | −0.5 (1.0) | <0.001 |
| Respiratory rate, breaths/min | 21.5 (3.5) | 20.8 (5.1) | 0.082 |
| Viral load category, copies/mL | – | ||
| <50, n (%) | 369 (77.9) | ||
| 50 to 1000, n (%) | 46 (9.7) | ||
| 1001 to 10,000, n (%) | 32 (6.8) | ||
| >10,000, n (%) | 26 (5.5) | ||
| CD4 count, cells/mm3 | 712 (571 to 959) | – | |
| WHO HIV staging at HIV diagnosis, n (%) | |||
| I | 34 (7.2) | ||
| II | 47 (9.9) | ||
| III | 266 (56.1) | ||
| IV | 105 (22.2) | ||
| ART used | |||
| NNRTI+2NRTI | 282 (59.5) | ||
| PI+2NRTI | 175 (36.9) | ||
| Others | 9 (1.9) | ||
| Previous PTB, n (%) | 287 (58.5) | 2 (0) | <0.001 |
| Previous severe LRTI, n (%) | 134 (28.3) | 1 (0.9) | <0.001 |
| Tobacco smoke exposure, n (%) | 119 (25.0) | 22 (20.9) | 0.279 |
| Poor ART adherence, n (%) | 111 (23.4) |
| |
| ART duration, years, n (%) | 7.0 (3.0) |
| |
| Age at ART initiation, years | 4.4 (2.0 to 7.0) | ||
| Shortness of breath, n (%) | 16 (3.4) | 2 (1.8) | 0.402 |
| History of wheeze, n (%) | 51 (10.8) | 6 (5.5) | 0.096 |
| History of cough, n (%) | 69 (14.6) | 8 (7.3) | 0.045 |
| History of doctor‐diagnosed asthma, n (%) | 57 (12.0) | 6 (5.5) | 0.048 |
| Finger clubbing, n (%) | 16 (3.5) | 0 | 0.052 |
ART, antiretroviral therapy; LRTI, lower respiratory tract infections; NNRTI, non‐nucleoside reverse transcriptase inhibitor; NRTI, nucleoside reverse transcriptase inhibitor; PI, protease inhibitor; PTB, pulmonary tuberculosis; WHO, World Health Organization.
Values are mean/SD except for age at ART initiation, viral load and CD4 which are median (IQR). *p values derived from chi‐square or two sample t‐test.
Figure 2Spirometry pattern and right ventricle function
Cardiopulmonary measurements by HIV status
| Variable, n (%) | n | HIV‐positive | n | HIV‐uninfected |
|
|---|---|---|---|---|---|
| Restrictive spirometry | 474 | 110 (23.2) | 109 | 23 (21.1) | 0.637 |
| Obstructive spirometry | 474 | 23 (4.9) | 109 | 4 (3.4) | 0.596 |
| Mixed pattern spirometry | 474 | 22 (4.6) | 109 | 0 | 0.022 |
| FEF25 to 75 below LLN | 474 | 76 (16.0) | 109 | 6 (5.5%) | 0.004 |
| Right ventricular dysfunction (low TAPSE and low FAC) | 474 | 154 (32.5) | 109 | 29 (26.6) | 0.232 |
| Pulmonary hypertension | 474 | 2 (0.46) | 109 | 0 | 0.476 |
| Left ventricular diastolic dysfunction | 474 | 36 (7.6) | 109 | 6 (5.5) | 0.447 |
| Left ventricle systolic dysfunction | 474 | 1 (0.2) | 109 | 0 | 0.631 |
| Cardiopulmonary function (impaired) | 474 | 64 (13.5) | 109 | 9 (8.3) | 0.136 |
| Pulse before walk (mean/SD) | 478 | 78.6 (12.5) | 104 | 82.9 (14.2) | 0.002 |
| Pulse after walk (mean/SD) | 478 | 82.9 (13.8) | 104 | 87.1 (15.0) | 0.004 |
| Oxygen saturation before walk (mean/SD) | 478 | 98.4 (2.0) | 104 | 98.6 (0.8)) | 0.315 |
| Oxygen saturation after walk (mean/SD) | 478 | 98.3 (2.7) | 104 | 98.4 (1.4) | 0.675 |
| MAP before 6MWT (mean/SD) | 478 | 79.2 (7.7) | 104 | 82.6 (8.1) | <0.001 |
| MAP after 6MWT | 478 | 83.0 (8.7) | 104 | 86.6 (8.5) | 0.001 |
| Borg scale before 6MWT (mean/SD) | 478 | 0.1 (0.2) | 104 | 0.04 (0.2) | 0.577 |
| Borg scale after 6MWT (mean/SD) | 478 | 1.3 (0.6) | 104 | 1.3 (0.7) | 0.737 |
| Distance walked in 6 min (mean/SD) | 478 | 437.8 (60.4) | 104 | 443.8 (60.7) | 0.380 |
6MWT, six‐minute walk test; FAC, fractional area change, Borg scale (perceived exertion scale); FEF25 to 75, forced expiratory flow at 25% and 75% of forced vital capacity; LLN, lower limit of normal calculated from African American reference values 22; MAP, mean arterial pressure (calculated from blood pressure); TAPSE, tricuspid annular plane systolic excursion.
p value derived from chi‐square or two sample t‐test.
Figure 3Lung and cardiac functional abnormalities in perinatally HIV‐positive adolescents
FEF25‐75, forced expiratory flow at 25% and 75% of forced vital capacity; LLN, lower limit of normal calculated from African‐American reference values 22 ; LV, left ventricle; RV, right ventricle.
Lung function by tricuspid annular plane systolic excursion (TAPSE) index in HIV‐positive adolescents
| Lung function | n | Low TAPSE | n | Normal TAPSE |
|
|---|---|---|---|---|---|
| Mean/SD | Mean/SD | ||||
| FEV1 (L) | 114 | 1.5 (0.5) | 350 | 1.6 (0.4) | 0.011 |
| FVC (L) | 114 | 1.7 (0.5) | 350 | 1.8 (0.5) | 0.022 |
| FEF25 to 75 (L) | 114 | 2.0 (0.9) | 350 | 2.2 (0.8) | 0.041 |
| FEV1/FVC | 114 | 0.9 (0.1) | 350 | 0.9 (0.1) | 0.165 |
FEF25 to 75, forced expiratory flow at 25 to 75% of vital capacity; FEV1, forced expiratory volume in 1 sec; FVC, forced vital capacity; TAPSE, tricuspid annular plane systolic excursion.
p value from two sample t‐test.
Associations of impaired cardiopulmonary function (n = 569) in perinatally HIV‐positive and uninfected adolescents
| Variable | Univariate Odds ratio |
| 95% CI | Multivariate Odds ratio |
| 95% CI |
|---|---|---|---|---|---|---|
| Age | 1.1 | 0.365 | 0.9 to 1.2 | – | ||
|
| 0.8 | 0.017 | 0.6 to 0.9 | 0.7 | 0.010 | 0.5 to 0.9 |
|
| 0.7 | <0.001 | 0.5 to 0.8 | 0.7 | 0.009 | 0.5 to 0.9 |
| ETS exposure | 0.8 | 0.545 | 0.5 to 1.5 | – | ||
| Sex | 0.8 | 0.419 | 0.5 to 1.3 | – | ||
| Past LRTI | 1.6 | 0.124 | 0.9 to 2.7 | 1.4 | 0.321 | 0.7 to 2.5 |
| Past PTB | 2.1 | 0.013 | 1.2 to 3.9 | 2.3 | 0.017 | 1.2 to 4.4 |
| Viral load copies/mL | – | |||||
| 50 to 1000 | 0.8 | 0.677 | 0.3 to 2.2 | |||
| 1001 to 10,000 | 1.9 | 0.171 | 0.8 to 4.6 | |||
| >10,000 | 1.7 | 0.331 | 0.6 to 4.6 | |||
| ART duration | 1.1 | 0.062 | 1.0 to 1.2 | 1.1 | 0.228 | 0.9 to 1.2 |
ART, antiretroviral therapy; BMI, body mass index; ETS, environmental tobacco smoke; LRTI, lower respiratory tract infection; PTB, pulmonary tuberculosis.
Adjusted for HIV status. Logistic regression.
Association of respiratory symptoms/signs with impaired cardiopulmonary function (n = 569) in perinatally HIV‐positive and uninfected adolescents
| Symptom | Univariate | Multivariate | ||||
|---|---|---|---|---|---|---|
| OR | 95% CI |
| OR | 95% CI |
| |
| Wheeze | 1.5 | 0.7 to 3.2 | 0.249 | 1.4 | 0.7 to 3.0 | 0.369 |
| Shortness of breath | 0.9 | 0.2 to 3.8 | 0.831 | 0.8 | 0.2 to 3.7 | 0.808 |
| Cough | 1.6 | 0.8 to 3.0 | 0.180 | 1.5 | 0.8 to 2.9 | 0.253 |
| Digital clubbing | 5.2 | 1.9 to 14.0 | 0.001 | 4.5 | 1.6 to 12.3 | 0.004 |
| Asthma | 1.5 | 0.7 to 3.2 | 0.249 | 1.3 | 0.6 to 2.7 | 0.445 |
Symptoms are self‐reported except digital clubbing aphysician‐diagnosed asthma; badjusted for HIV status, age, sex, height. Logistic regression.